drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Autologous TCR-T cells engineered via mRNA to transiently express HBV antigen–specific T-cell receptors that recognize HBV peptides presented by HLA-A*02:01 or HLA-A*24:02 on tumor cells, driving TCR/MHC class I–dependent activation and cytotoxicity against HBV-related hepatocellular carcinoma; administered by weekly IV infusion at 5–10×10^6 cells/kg.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Immunotherapy, Adoptive
drug_category
ENGINEERED TCR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are transiently mRNA-engineered to express HBV-specific T-cell receptors that recognize HBV-derived peptides presented by HLA-A*02:01 or HLA-A*24:02 on tumor cells, triggering TCR/MHC class I–dependent activation and cytotoxic killing of HBV-related hepatocellular carcinoma cells.
drug_name
HBV antigen-specific TCR-redirected T cells
nct_id_drug_ref
NCT06961617